Kiniksa Pharmaceuticals (KNSA) to Release Quarterly Earnings on Wednesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Kiniksa Pharmaceuticals Stock Performance

Shares of Kiniksa Pharmaceuticals stock traded up $0.33 on Friday, hitting $20.02. The company's stock had a trading volume of 404,104 shares, compared to its average volume of 551,265. Kiniksa Pharmaceuticals has a 1 year low of $16.56 and a 1 year high of $28.15. The firm has a fifty day moving average price of $19.71 and a 200-day moving average price of $22.72. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -142.99 and a beta of 0.32.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on KNSA shares. JPMorgan Chase & Co. lifted their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Evercore ISI lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. Finally, Wedbush reiterated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $36.60.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the business's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $18.24, for a total transaction of $255,360.00. Following the transaction, the chief operating officer now directly owns 88,975 shares in the company, valued at $1,622,904. The trade was a 13.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark Ragosa sold 8,969 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,092 shares of company stock worth $745,589 in the last ninety days. Insiders own 54.57% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.